

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. A recent study published in *The New England Journal of Medicine* and subsequently updated at ASCO 2016 demonstrated that patients with metastatic colorectal cancer and _____ responded to treatment with the immune checkpoint inhibitor pembrolizumab.
 - a. Microsatellite stable tumors
 - b. Microsatellite instability (MSI)-high tumors
 - c. Both a and b
 - d. Neither a nor b
2. TAS-102 is an _____.
 - a. Anti-angiogenic agent
 - b. Antibody-drug conjugate
 - c. Anti-PD-1 antibody
 - d. Oral nucleoside
3. Which of the following side effects is typically associated with TAS-102 therapy?
 - a. Hepatic dysfunction
 - b. Neutropenia
 - c. Rash
 - d. Renal dysfunction
 - e. Vomiting
 - f. All of the above
4. Results of a Phase Ib study presented at ASCO 2016 evaluating the cancer stemness inhibitor napabucasin (BBI608) in combination with FOLFIRI with or without bevacizumab for metastatic colorectal cancer demonstrated that napabucasin _____ be safely combined with FOLFIRI with or without bevacizumab.
 - a. Could
 - b. Could not
5. Approximately what proportion of patients with gastric cancer have HER2-amplified disease?
 - a. Fewer than 20%
 - b. 35% to 50%
 - c. More than 50%
6. The Phase II/III GATSBY trial evaluating T-DM1 versus a taxane as second-line therapy for locally advanced or metastatic HER2-positive gastric or gastroesophageal cancer demonstrated a statistically significant overall survival improvement for patients receiving T-DM1.
 - a. True
 - b. False
7. The Phase III BRIGHTER trial is evaluating _____ with weekly paclitaxel versus placebo with weekly paclitaxel for previously treated gastric or gastroesophageal junction adenocarcinoma.
 - a. Napabucasin (BBI608)
 - b. Nivolumab
 - c. Regorafenib
 - d. TAS-102
8. Side effects that may be associated with ramucirumab include _____.
 - a. Hypertension
 - b. Nosebleeds
 - c. Bowel perforation
 - d. Thromboembolism
 - e. All of the above
9. Approximately what proportion of patients with squamous cell carcinoma of the esophagus exhibit PD-L1 expression?
 - a. 10%
 - b. 25%
 - c. 50%
 - d. 100%
10. The Phase III CRITICS study presented at ASCO 2016 evaluating neoadjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiation therapy for patients with resectable gastric cancer reported no significant difference in overall survival between postoperative chemotherapy and chemoradiation therapy.
 - a. True
 - b. False